We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DENTSPLY (XRAY) Q1 Earnings Miss Estimates, Sales Up Y/Y
Read MoreHide Full Article
DENTSPLY SIRONA Inc (XRAY - Free Report) is one of the leading worldwide manufacturers’ dental consumables, dental laboratory products, dental specialty products and consumable medical device products. Post DENTSPLY-SIRONA merger, the business has been organized into two reporting segments: Dental & Healthcare Consumables and Technologies.
Currently, this York, PA- based company carries a Zacks Rank #3 (Hold) but that could change following its first quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: DENTSPLY reported adjusted earnings of 49 cents per share, which missed the Zacks Consensus Estimate by 2 cents and was lower than earnings of 69 cents in the year-ago quarter.
Revenues: DENTSPLY’s net sales increased to $900.5 million from $772.6 million in the year-ago period. However this came below the Zacks Consensus Estimate of $917.0 million. Sales of the combined businesses fell 2.2% at constant currency (cc) basis.
Key Stats: Dental and Healthcare Consumables sales rose 2.8% year over year at cc, while Technologies fell 8.1% in the quarter.
Major Factors: U.S. business in the first quarter was negatively impacted by inventory reduction related to a change in distribution strategy in North America. The company expects adjusted EPS for full year 2017 in the range of $2.80 to $2.90 per diluted share.
Check back later for our full write up on this DENTSPLY earnings report later!
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
Image: Bigstock
DENTSPLY (XRAY) Q1 Earnings Miss Estimates, Sales Up Y/Y
DENTSPLY SIRONA Inc (XRAY - Free Report) is one of the leading worldwide manufacturers’ dental consumables, dental laboratory products, dental specialty products and consumable medical device products. Post DENTSPLY-SIRONA merger, the business has been organized into two reporting segments: Dental & Healthcare Consumables and Technologies.
Currently, this York, PA- based company carries a Zacks Rank #3 (Hold) but that could change following its first quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: DENTSPLY reported adjusted earnings of 49 cents per share, which missed the Zacks Consensus Estimate by 2 cents and was lower than earnings of 69 cents in the year-ago quarter.
Revenues: DENTSPLY’s net sales increased to $900.5 million from $772.6 million in the year-ago period. However this came below the Zacks Consensus Estimate of $917.0 million. Sales of the combined businesses fell 2.2% at constant currency (cc) basis.
DENTSPLY SIRONA Inc. Price and EPS Surprise
DENTSPLY SIRONA Inc. Price and EPS Surprise | DENTSPLY SIRONA Inc. Quote
Key Stats: Dental and Healthcare Consumables sales rose 2.8% year over year at cc, while Technologies fell 8.1% in the quarter.
Major Factors: U.S. business in the first quarter was negatively impacted by inventory reduction related to a change in distribution strategy in North America. The company expects adjusted EPS for full year 2017 in the range of $2.80 to $2.90 per diluted share.
Check back later for our full write up on this DENTSPLY earnings report later!
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>